var data={"title":"Nontuberculous mycobacterial lymphadenitis in children","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Nontuberculous mycobacterial lymphadenitis in children</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/contributors\" class=\"contributor contributor_credentials\">Andrea T Cruz, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/contributors\" class=\"contributor contributor_credentials\">Morven S Edwards, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/contributors\" class=\"contributor contributor_credentials\">Mary M Torchia, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jun 07, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H2272512883\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Nontuberculous mycobacteria (NTM) are a miscellaneous collection of acid-fast bacteria that are widespread in the environment [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1\" class=\"abstract_t\">1</a>]. They have been isolated from numerous environmental sources including water, soil, food products, and domestic and wild animals [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Health care-associated transmission has occurred with medical equipment [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/3-5\" class=\"abstract_t\">3-5</a>].</p><p>More than 130 species of have been identified, not all of which have been documented to cause disease in humans [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/6-9\" class=\"abstract_t\">6-9</a>]. NTM pathogens are classified as rapidly growing or slowly growing (<a href=\"image.htm?imageKey=ID%2F61936\" class=\"graphic graphic_table graphicRef61936 \">table 1</a>). Rapidly growing species grow within seven days and include <em>Mycobacterium fortuitum, M. abscessus,</em> and <em>M. chelonae</em>. Slowly growing species require several weeks to grow and include <em>M. avium </em>complex,<em> M. marinum, </em>and<em> M. kansasii</em>. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H2\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Classification'</a>.)</p><p>NTM can cause a broad range of infections that vary depending on the particular NTM species and the host. In children, NTM cause four main clinical syndromes: lymphadenitis, skin and soft tissue infection (SSTI), pulmonary disease (predominantly in children with underlying pulmonary conditions), and disseminated disease (predominantly in children with immune compromise).</p><p>This topic will provide an overview of NTM lymphadenitis in children. NTM SSTI, pulmonary infections, disseminated infections, and bacteremia in children are discussed separately. (See <a href=\"topic.htm?path=nontuberculous-mycobacterial-skin-and-soft-tissue-infections-in-children\" class=\"medical medical_review\">&quot;Nontuberculous mycobacterial skin and soft tissue infections in children&quot;</a> and <a href=\"topic.htm?path=nontuberculous-mycobacterial-pulmonary-infections-in-children\" class=\"medical medical_review\">&quot;Nontuberculous mycobacterial pulmonary infections in children&quot;</a> and <a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children\" class=\"medical medical_review\">&quot;Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2272512896\"><span class=\"h1\">MICROBIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In case series of nontuberculous mycobacterial lymphadenitis among children in the United States, the majority of cases are caused by <em>M. avium</em> complex (MAC), which includes <em>M. avium</em> and <em>M. intracellulare </em>[<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,10,11\" class=\"abstract_t\">2,10,11</a>]. In series from other countries, MAC and <em>M. haemophilum </em>are frequently isolated [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/12-16\" class=\"abstract_t\">12-16</a>].</p><p class=\"headingAnchor\" id=\"H2272512904\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Estimates of the true burden of nontuberculous mycobacterial (NTM) infections in children are unavailable; in part because NTM infections may be asymptomatic and because NTM infections are not communicable, reporting of NTM infections is not required in the United States or many other countries [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Nonetheless, the overall prevalence of NTM disease appears to be increasing (possibly as a result of enhanced detection) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,17-20\" class=\"abstract_t\">10,17-20</a>]. (See <a href=\"topic.htm?path=epidemiology-of-nontuberculous-mycobacterial-infections\" class=\"medical medical_review\">&quot;Epidemiology of nontuberculous mycobacterial infections&quot;</a>.)</p><p>In population-based surveillance studies, estimates of the annual incidence of NTM in children range widely: from 0.6 to 1.6 per 100,000 children in Australia, to 3.1 per 100,000 children in Germany, to 77 per 100,000 children in the Netherlands [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/21-24\" class=\"abstract_t\">21-24</a>]. In each of these studies, lymphadenitis was the most common presentation.</p><p>NTM are transmitted through environmental sources. <em>M. avium</em> complex (MAC), the most common cause of lymphadenitis, is found in soil and water (from both natural and treated water) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/25-29\" class=\"abstract_t\">25-29</a>]. Aquatic transmission of NTM is facilitated by the formation of biofilms, which permit survival under a variety of environmental conditions and allow dissemination of large numbers of organisms when they become detached [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/30\" class=\"abstract_t\">30</a>].</p><p>Most cases of NTM lymphadenitis occur in immunocompetent children [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,10,22\" class=\"abstract_t\">1,10,22</a>]. However, an association between NTM cervicofacial lymphadenitis and interleukin-1B polymorphisms has been reported [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/31\" class=\"abstract_t\">31</a>]. Children with a history of bacille Calmette-Gu&eacute;rin immunization appear to have a reduced risk of MAC lymphadenitis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/32,33\" class=\"abstract_t\">32,33</a>].</p><p>The oropharyngeal mucosa is the typical portal of entry for NTM cervical lymphadenitis. Lymphadenitis in other sites may follow penetrating trauma [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,34\" class=\"abstract_t\">10,34</a>].</p><p>The incubation period is variable [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/9\" class=\"abstract_t\">9</a>].</p><p class=\"headingAnchor\" id=\"H2272512912\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Lymphadenitis is the most common manifestation of nontuberculous mycobacterial (NTM) disease in childhood. It typically occurs in children between one and five years of age [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,13,24,35\" class=\"abstract_t\">10,13,24,35</a>]. The cervicofacial nodes, particularly the submandibular nodes, are most frequently involved [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,24\" class=\"abstract_t\">10,24</a>]. Lymph nodes outside the head and neck, including hilar or mediastinal nodes, may also be involved.</p><p>NTM lymphadenitis generally presents as a unilateral, nontender node (&lt;4 cm in diameter) that slowly enlarges over several weeks [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/36\" class=\"abstract_t\">36</a>]. The overlying skin gradually changes from pink to violaceous and thins to become parchment-like (<a href=\"image.htm?imageKey=PEDS%2F69475\" class=\"graphic graphic_picture graphicRef69475 \">picture 1</a>) and may eventually suppurate through a sinus tract [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,10,24,36\" class=\"abstract_t\">1,10,24,36</a>]. Sinus tract formation can occur spontaneously or follow direct trauma to the region. Fever and other systemic findings are variable [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/22,23\" class=\"abstract_t\">22,23</a>]. If prescribed, antibiotics directed against staphylococci or streptococci generally are not helpful [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,20,36,37\" class=\"abstract_t\">1,20,36,37</a>]. These features do not reliably differentiate NTM from <em>M. tuberculosis</em> lymphadenitis. (See <a href=\"#H2272513023\" class=\"local\">'Differential diagnosis'</a> below.)</p><p>Delay in diagnosis is common. In a series of 105 patients, the time between onset of swelling and diagnosis was typically four to eight weeks (median 6.5 weeks, range eight days to two years) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10\" class=\"abstract_t\">10</a>].</p><p>The clinical features of NTM lymphadenitis have been described in several case series, each including &gt;100 children [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,22,24,35\" class=\"abstract_t\">10,22,24,35</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The submandibular nodes were involved in 87 percent, followed by preauricular (9 percent) and submental (3 percent) nodes; supraclavicular node involvement was uncommon [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/35\" class=\"abstract_t\">35</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nearly all cases are of cervical adenitis were unilateral (89 to 99 percent) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,22,35\" class=\"abstract_t\">10,22,35</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Violaceous discoloration and fluctuance were present in 85 percent [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/35\" class=\"abstract_t\">35</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Fever (T &gt;38.5&deg;C [101.3&deg;F]) was present in 13 to 21 percent [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/22,24\" class=\"abstract_t\">22,24</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one series, a fistula developed in 14 of 84 patients (16.7 percent) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/22\" class=\"abstract_t\">22</a>]; in another, a draining sinus tract was noted on follow-up ultrasonography in 62 of 66 (93 percent) patients who were initially treated with antibiotics, but without excision [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/35\" class=\"abstract_t\">35</a>]</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymph nodes in addition to those in the cervicofacial region were involved in 15 percent of cases in one series (86 percent of such cases were caused by <em>M. haemophilum</em>, 14 percent by <em>M. avium</em>) and 29 percent in another [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,35\" class=\"abstract_t\">10,35</a>]</p><p/><p class=\"headingAnchor\" id=\"H2272512920\"><span class=\"h1\">RADIOGRAPHIC FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Imaging studies are not necessary in the routine evaluation of a child with suspected nontuberculous mycobacterial (NTM) adenitis but may be helpful in evaluating other conditions in the differential diagnosis of cervical adenitis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/38\" class=\"abstract_t\">38</a>]. (See <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;</a> and <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-etiology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Etiology and clinical manifestations&quot;</a>.)</p><p>Ultrasonographic features of NTM lymphadenitis were described in case series in which ultrasonography was performed on 145 children who participated in a clinical trial [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/35\" class=\"abstract_t\">35</a>]. Early in the disease course, decreased echogenicity was noted in all patients; in the advanced stages, 92 percent had intranodal liquefaction, matted nodes, and soft tissue edema.</p><p>Computed tomography findings of NTM lymphadenitis include ring-enhancement with central hypodensity and minimal to absent fat stranding; the lack of fat stranding may help to differentiate NTM from pyogenic lymphadenitis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/35,39,40\" class=\"abstract_t\">35,39,40</a>].</p><p>Chest radiograph may be performed to look for signs of pulmonary tuberculosis or malignancy (eg, hilar adenopathy). The chest radiograph is typically normal in children with NTM lymphadenitis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,41\" class=\"abstract_t\">2,41</a>].</p><p class=\"headingAnchor\" id=\"H2272512928\"><span class=\"h1\">LABORATORY FEATURES</span></p><p class=\"headingAnchor\" id=\"H2272512935\"><span class=\"h2\">Acid-fast bacilli stains and histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Positive staining for acid-fast bacilli (AFB) on samples of fistula drainage or biopsy specimens in children with nontuberculous mycobacterial (NTM) lymphadenitis is variable [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/19,21,39\" class=\"abstract_t\">19,21,39</a>]. Negative AFB stains do not exclude mycobacterial disease, and positive AFB stains do not distinguish NTM from<em> M. tuberculosis</em>. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H3\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Microscopy'</a>.)</p><p>Histopathologic features of NTM lymphadenitis include caseating granulomas, necrotizing granulomas, granulomatous and pyogenic inflammation, mononuclear inflammation, fibrocaseous reactions, multinucleated giant cells, and microabscesses [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,39,42\" class=\"abstract_t\">10,39,42</a>]. These histologic features overlap with those of <em>M. tuberculosis</em>. (See <a href=\"#H2272513023\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H2272512943\"><span class=\"h2\">Other tests</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with NTM lymphadenitis usually have normal complete blood count (CBC), differential, and erythrocyte sedimentation rate (ESR) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/17,24\" class=\"abstract_t\">17,24</a>]. Abnormal findings in the CBC <span class=\"nowrap\">and/or</span> elevated ESR should prompt consideration of other conditions in the differential diagnosis. (See <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-etiology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Etiology and clinical manifestations&quot;</a> and <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2272512951\"><span class=\"h1\">DIAGNOSIS</span></p><p class=\"headingAnchor\" id=\"H2377830849\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Definitive diagnosis of nontuberculous mycobacterial (NTM) lymphadenitis requires isolation of NTM from culture or polymerase chain reaction (PCR) of fistula drainage, tissue, or caseous material [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,10,17\" class=\"abstract_t\">1,10,17</a>]. (See <a href=\"#H2443738274\" class=\"local\">'Microbiology/histopathology'</a> below.)</p><p>Among children with a negative culture or in whom culture results are pending, a presumptive diagnosis of NTM lymphadenitis can be made if the clinical (eg, <span class=\"nowrap\">subacute/chronic</span> nontender, unilateral lymphadenitis, violaceous discoloration) <span class=\"nowrap\">and/or</span> histopathologic features (eg, positive stains for acid-fast bacilli [AFB], granulomas) are compatible with NTM and other conditions in the differential diagnosis (including <em>M. tuberculosis</em>) have been excluded [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,10,17,39,43\" class=\"abstract_t\">1,10,17,39,43</a>]. (See <a href=\"#H2272512912\" class=\"local\">'Clinical features'</a> above and <a href=\"#H2272512928\" class=\"local\">'Laboratory features'</a> above and <a href=\"#H2272513023\" class=\"local\">'Differential diagnosis'</a> below.)</p><p class=\"headingAnchor\" id=\"H2272512967\"><span class=\"h2\">Clinical suspicion</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>NTM should be suspected in young children (&lt;5 years) with <span class=\"nowrap\">subacute/chronic</span> (ie, &gt;3 weeks), unilateral, nontender, cervicofacial lymphadenitis that fails to improve or worsens despite antibiotic therapy directed against staphylococci and streptococci (if such therapy has been provided) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1\" class=\"abstract_t\">1</a>]. Patients are usually well appearing without constitutional symptoms.</p><p>The clinical course and appearance of NTM adenitis, particularly when the overlying skin becomes violaceous and thin, often is so characteristic that a presumptive diagnosis can be made based upon the history and physical examination (<a href=\"image.htm?imageKey=PEDS%2F69475\" class=\"graphic graphic_picture graphicRef69475 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1\" class=\"abstract_t\">1</a>]. (See <a href=\"#H2272512912\" class=\"local\">'Clinical features'</a> above.)</p><p>However, early in the course of disease, particularly before the skin becomes violaceous, other conditions in the differential diagnosis may appear more likely, and evaluation and treatment for such conditions may be undertaken before NTM is suspected. This evaluation may include complete blood count with differential and erythrocyte sedimentation rate, tuberculin skin testing (TST), interferon gamma release assay, imaging, <span class=\"nowrap\">and/or</span> serologic testing (as clinically indicated for <em>Bartonella henselae</em>, Epstein-Barr virus, cytomegalovirus, human immunodeficiency virus, toxoplasmosis, etc). (See <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management#H15\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;, section on 'Subacute/chronic'</a>.)</p><p class=\"headingAnchor\" id=\"H2443737761\"><span class=\"h2\">Tuberculin skin testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>TST can help to narrow the differential diagnosis in a child with suspected NTM lymphadenitis, but the interpretation depends upon risk factors for <em>M. tuberculosis</em> and receipt of bacille Calmette-Gu&eacute;rin (BCG) vaccination.</p><p>In children <strong>without</strong> risk factors for <em>M. tuberculosis</em> and who have not received BCG vaccination, TST with &ge;5 mm induration at 48 hours supports a diagnosis of NTM infection. In a study of 174 children with cervicofacial lymphadenitis who had no exposure to <em>M. tuberculosis</em> and had not received BCG vaccination, TST with &gt;5 mm of induration at 48 hours had a sensitivity, specificity, and positive and negative predictive value of 70 percent, 98 percent, 98 percent, and 64 percent, respectively for NTM (confirmed by positive culture <span class=\"nowrap\">and/or</span> polymerase chain reaction) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/12\" class=\"abstract_t\">12</a>].</p><p>In children <strong>with</strong> risk factors for <em>M. tuberculosis</em>, TST &ge;5 mm does not distinguish between NTM and <em>M. tuberculosis</em> [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,12,38,44\" class=\"abstract_t\">2,12,38,44</a>]. TST &ge;15 mm may be more suggestive of <em>M. tuberculosis</em> than NTM but does not exclude NTM. In an observational study of 29 children with culture-confirmed NTM lymphadenitis, 17 (59 percent) had induration &ge;15 mm [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/44\" class=\"abstract_t\">44</a>]; most of these children had <em>M. avium </em>complex or <em>M. haemophilum</em> lymphadenitis. In children with suspected NTM lymphadenitis and TST &ge;5 mm induration, interferon gamma release assays testing may be helpful [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/45\" class=\"abstract_t\">45</a>]. (See <a href=\"#H2272513031\" class=\"local\">'M. tuberculosis'</a> below.)</p><p>Independent of risk factors for <em>M. tuberculosis</em>, TST with &lt;5 mm of induration at 48 hours is not helpful in excluding mycobacterial disease. If NTM continues to be suspected in a child with negative TST, specimens should be obtained and sent for microbiologic and histopathologic studies. (See <a href=\"#H2443738274\" class=\"local\">'Microbiology/histopathology'</a> below.)</p><p class=\"headingAnchor\" id=\"H2443738274\"><span class=\"h2\">Microbiology/histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Tissue specimens <span class=\"nowrap\">and/or</span> aspirated fluid or pus should be sent for AFB stains, histopathology, and mycobacterial culture or PCR (in addition to bacterial and fungal stains and cultures, and cytopathology as clinically indicated).</p><p>Isolation of NTM from culture or PCR of fistula drainage, tissue, or caseous material confirms the diagnosis of NTM lymphadenitis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Pending culture results, positive AFB stains and characteristic histopathology can help to establish a presumptive diagnosis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,10,17,39,43\" class=\"abstract_t\">1,10,17,39,43</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Obtaining and processing specimens</strong> &ndash; Specimens for microbiologic and histopathologic studies in children with suspected NTM may be obtained through excisional biopsy, fine needle aspiration, or fistulous drainage. If there is a strong suspicion of NTM, excisional biopsy often is undertaken because it is curative; in addition the yield is usually better than with fine needle aspiration [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,2,39\" class=\"abstract_t\">1,2,39</a>]. However, some advocate fine needle aspiration for obtaining diagnostic material [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/13,43\" class=\"abstract_t\">13,43</a>]. (See <a href=\"#H2272513047\" class=\"local\">'Management'</a> below.)</p><p/><p class=\"bulletIndent1\">Incision and drainage generally are contraindicated if NTM is suspected because of the risk of recurrence or development of a chronically draining fistula [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,46-49\" class=\"abstract_t\">1,46-49</a>]. However, incision and drainage may have been performed before NTM was suspected. (See <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;</a>.)</p><p/><p class=\"bulletIndent1\">It is helpful to discuss specimen collection, transport, and processing with the microbiology laboratory before sending tissue or fluid samples for suspected NTM. Some species of NTM (eg, <em>M. haemophilum</em>) have fastidious growth requirements.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>AFB stains and histopathology</strong> &ndash; Positive stains for AFB and histopathology with characteristic features (eg, granulomas, granulomatous and pyogenic inflammation, mononuclear inflammation, fibrocaseous reactions, multinucleated giant cells, and microabscesses) support a diagnosis of mycobacterial infection [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,39,42\" class=\"abstract_t\">10,39,42</a>]. However, AFB staining cannot distinguish among NTM species or between NTM species and <em>M. tuberculosis</em>. Negative AFB stains do not exclude mycobacterial disease. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H3\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Microscopy'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Culture</strong> &ndash; A positive culture confirms the diagnosis of NTM lymphadenitis. However, isolation and identification of the NTM species may take longer than six weeks [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/12\" class=\"abstract_t\">12</a>]. The yield of positive NTM cultures from excised lymph nodes ranges from 50 to 80 percent [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,10\" class=\"abstract_t\">2,10</a>]. The yield is usually lower for specimens obtained through fine needle aspirate, though yields of up to 80 percent have been reported [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/13\" class=\"abstract_t\">13</a>].</p><p/><p class=\"bulletIndent1\">Microbiologic techniques to maximize the yield of NTM cultures are discussed separately. (See <a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria#H4\" class=\"medical medical_review\">&quot;Microbiology of nontuberculous mycobacteria&quot;, section on 'Culture'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>PCR</strong> &ndash; The diagnosis of NTM infection can be established with species-specific or multiplex PCR testing [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,50-52\" class=\"abstract_t\">2,50-52</a>]. PCR tests that can identify <em>M. avium</em> complex soon after growth is evident are commercially available [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/53\" class=\"abstract_t\">53</a>]. In a study of 67 children with mycobacterial adenitis and 50 children with cat scratch disease, the sensitivity and specificity of mycobacterial PCR were 72 and 100 percent, respectively [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/50\" class=\"abstract_t\">50</a>]. The performance of PCR is based upon the quality of the specimen. Sending lymphatic tissue for culture and molecular testing is superior to sending exudative material; sending swabs of drainage is suboptimal.</p><p/><p class=\"headingAnchor\" id=\"H2272513023\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis of nontuberculous mycobacterial (NTM) lymphadenitis includes other infectious causes of unilateral lymphadenitis (eg, <em>Staphylococcus aureus</em>,<em> Streptococcus pyogenes</em>, <em>B. henselae</em>, <em>M. tuberculosis</em>, viral infections, toxoplasmosis), benign cysts, and malignancy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,10,41,54\" class=\"abstract_t\">1,10,41,54</a>]. Historical, examination, and laboratory findings (eg, blood counts, erythrocyte sedimentation rate, serology) may be helpful in differentiating NTM lymphadenitis from these conditions. (See <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-etiology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Etiology and clinical manifestations&quot;</a> and <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2272513031\"><span class=\"h2\">M. tuberculosis</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is particularly important to try to distinguish between NTM and <em>M. tuberculosis</em> lymphadenitis because they have different public health and treatment implications [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Culture is necessary for definitive diagnosis. (See <a href=\"#H2443738274\" class=\"local\">'Microbiology/histopathology'</a> above and <a href=\"topic.htm?path=tuberculous-lymphadenitis#H5\" class=\"medical medical_review\">&quot;Tuberculous lymphadenitis&quot;, section on 'Cervical lymphadenopathy'</a>.)</p><p>No clinical or histopathologic feature reliably differentiates NTM from <em>M. tuberculosis</em> lymphadenitis. However, in observational studies certain features were more suggestive of NTM [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/11,41,42\" class=\"abstract_t\">11,41,42</a>]. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Younger age (ie, preschool)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of risk factors for tuberculosis, including being born in a country with low prevalence of <em>M. tuberculosis</em></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Normal chest radiograph</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Negative tuberculin skin testing (TST) results in family members</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Negative interferon-gamma release assay</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Ill-defined (nonpalisading), irregular, serpiginous, or sarcoid granulomas</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Polymorphonuclear leukocytes in center of areas of necrosis rather than diffusely scattered</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lack of significant caseation</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Microabscesses</p><p/><p>Interferon gamma release assays (IGRA) may be helpful in differentiating NTM from <em>M. tuberculosis </em>in children with TST &ge;5 mm at 48 hours [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/45\" class=\"abstract_t\">45</a>]. A negative IGRA suggests NTM, whereas a positive IGRA suggests <em>M. tuberculosis</em> [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/38\" class=\"abstract_t\">38</a>].<em> </em>IGRAs do not cross-react with the NTM species that most frequently cause lymphadenitis (<em>M. avium</em>, <em>M. haemophilum</em>, and <em>M. scrofulaceum</em>), but they may cross-react with other species (<em>M. flavescens, M. kansasii</em>, <em>M. marinum</em>, and<em> M. szulgai</em>). Unfortunately, IGRAs often are indeterminate in children younger than five years, the predominant age group for NTM lymphadenitis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/55\" class=\"abstract_t\">55</a>]. (See <a href=\"topic.htm?path=use-of-interferon-gamma-release-assays-for-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults#H4850554\" class=\"medical medical_review\">&quot;Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;, section on 'Assay antigens'</a> and <a href=\"topic.htm?path=use-of-interferon-gamma-release-assays-for-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">&quot;Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2272513039\"><span class=\"h2\">Other conditions</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In contrast to lymphadenitis due to other bacterial pathogens, NTM lymphadenitis has a more <span class=\"nowrap\">subacute/chronic</span> course, lacks warmth and tenderness, and often has overlying violaceous skin discoloration; TST testing may be positive, but other laboratory findings usually are normal. (See <a href=\"#H2272512912\" class=\"local\">'Clinical features'</a> above and <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-etiology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Etiology and clinical manifestations&quot;</a> and <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2272513047\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of nontuberculous mycobacterial (NTM) lymphadenitis in children may require surgery <span class=\"nowrap\">and/or</span> antimycobacterial therapy, in combination or sequentially. When discussing the benefits and risks of these modalities, parents should be advised that clinical response to both surgical and medical management may be incomplete and additional procedures and therapies may be necessary. If the diagnosis is uncertain and the surgical risks (eg, facial nerve injury) preclude surgical excision, fine-needle aspiration may help establish the microbiologic diagnosis with minimal procedural risk. (See <a href=\"#H2272513063\" class=\"local\">'Surgical excision'</a> below and <a href=\"#H2443738274\" class=\"local\">'Microbiology/histopathology'</a> above.)</p><p class=\"headingAnchor\" id=\"H2272513063\"><span class=\"h2\">Surgical excision</span></p><p class=\"headingAnchor\" id=\"H2377831009\"><span class=\"h3\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with NTM or suspected NTM lymphadenitis and no evidence of pulmonary or disseminated disease, we suggest surgical excision without antimicrobial therapy as the initial intervention if excision can be performed safely (eg, without damage to the facial nerve (<a href=\"image.htm?imageKey=NEURO%2F55677\" class=\"graphic graphic_figure graphicRef55677 \">figure 1</a>)). Surgical excision is curative and provides the optimal specimen for diagnostic testing [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,2,56-59\" class=\"abstract_t\">1,2,56-59</a>]. Incision and drainage generally are contraindicated because of the high probability of developing a chronically draining sinus tract, and increased risk of recurrence [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,46-49\" class=\"abstract_t\">1,46-49</a>]. (See <a href=\"#H2443738274\" class=\"local\">'Microbiology/histopathology'</a> above.)</p><p>The management of pulmonary and disseminated NTM disease in children is discussed separately. (See <a href=\"topic.htm?path=nontuberculous-mycobacterial-pulmonary-infections-in-children#H1060354672\" class=\"medical medical_review\">&quot;Nontuberculous mycobacterial pulmonary infections in children&quot;, section on 'Treatment'</a> and <a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children#H564807864\" class=\"medical medical_review\">&quot;Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children&quot;, section on 'Treatment'</a>.)</p><p>In a randomized trial and observational studies, surgical excision has been associated with higher rates of cure, <span class=\"nowrap\">improved/more</span> rapid healing, better cosmetic results, and fewer adverse effects than curettage, antimicrobial therapy, or observation [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1,24,37,56,57,59,60\" class=\"abstract_t\">1,24,37,56,57,59,60</a>].</p><p>Surgical and medical therapy of NTM lymphadenitis were compared in a trial in which 100 children were randomly assigned to surgical excision or antimicrobial therapy with <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> and <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a> for at least 12 weeks (and up to six months) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/57\" class=\"abstract_t\">57</a>]. <em>M. avium </em>complex (MAC) was isolated in 71 percent of children; none of the isolates were macrolide resistant. The following findings were noted:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The rate of cure (defined as regression of the lymph node enlargement by at least 75 percent, cure of the fistula, and total skin closure without local recurrence or de novo lesions after six months) was greater in the patients treated with excision (96 versus 66 percent).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Only 4 percent of children treated with surgical management had recurrence or development of new lesions; draining fistula developed in 32 percent of children treated with antibiotics.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Surgical complications occurred in 28 percent of the surgical patients: staphylococcal wound infection in six, postoperative hematoma in one, temporary dysfunction of the marginal mandibular branch of the facial nerve in six, and permanent dysfunction of the marginal mandibular branch of the facial nerve in one; adverse effects related to medication or disease progression occurred in 78 percent of patients treated with antibiotics.</p><p/><p>In a randomized trial comparing surgical excision and surgical curettage for NTM lymphadenitis in 50 children with culture- or polymerase chain reaction- (PCR) confirmed NTM lymphadenitis, wound healing was shorter with excision (3.6 versus 11.4 weeks) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/59\" class=\"abstract_t\">59</a>]. However, 16 percent of patients in the excision group had transient weakness of the facial nerve, compared with none of the patients who underwent curettage. In another series of 45 children with cervicofacial NTM lymphadenitis who had surgical management (eg, parotidectomy with or without lymphadenectomy), 32 percent had facial nerve paresis, 21 percent had poor wound healing, 14 percent had postoperative infection, 9 percent had recurrence, and 5 percent had facial nerve paralysis [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/61\" class=\"abstract_t\">61</a>]. In a retrospective cohort of 71 children with complex cervicofacial NTM lymphadenitis who were treated with surgical excision (with or without medical therapy), postoperative facial nerve weakness occurred in approximately 25 percent of patients and typically resolved within 12 months [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/62\" class=\"abstract_t\">62</a>].</p><p>Surgical excision of NTM lymphadenitis is recommended by the American Thoracic Society, Infectious Diseases Society of America (IDSA), and the American Academy of Pediatrics (AAP) Committee on Infectious Diseases [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>].</p><p class=\"headingAnchor\" id=\"H2272513071\"><span class=\"h3\">Postoperative follow-up</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Children with isolated NTM lymphadenitis that has been successfully excised can be discharged from follow-up when their wound is healed. However, they should be informed that there is a small (&lt;5 percent) risk of recurrence or development of new lesions [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/57\" class=\"abstract_t\">57</a>] and instructed to return to medical attention if they notice any changes in the lesion. Recurrences may be treated surgically or with antimycobacterial therapy.</p><p class=\"headingAnchor\" id=\"H2272513094\"><span class=\"h3\">Postoperative recurrence</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is limited evidence to guide treatment of recurrent NTM lymphadenitis following surgical excision or antimicrobial therapy. In clinical trials and observational studies, recurrent NTM lymphadenitis has been successfully treated with surgical excision (if it can be performed safely) or antimycobacterial therapy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/57\" class=\"abstract_t\">57</a>].</p><p class=\"headingAnchor\" id=\"H2272513102\"><span class=\"h2\">Antimycobacterial therapy</span></p><p class=\"headingAnchor\" id=\"H2377831016\"><span class=\"h3\">Indications</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For children with isolated NTM lymphadenitis or suspected NTM lymphadenitis who are not candidates for surgical excision (eg, increased risk of facial nerve damage [eg, preauricular or intraparotid involvement (<a href=\"image.htm?imageKey=NEURO%2F55677\" class=\"graphic graphic_figure graphicRef55677 \">figure 1</a>)] or poor cosmetic result, established sinus tract, etc), we suggest antimicrobial therapy with or without subsequent gentle curettage rather than observation (ie, wait-and-see). The prolonged course of spontaneous resolution may make observation intolerable for many <span class=\"nowrap\">patients/parents</span> [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/13,63\" class=\"abstract_t\">13,63</a>]. (See <a href=\"#H2272513142\" class=\"local\">'Observation'</a> below.)</p><p>Randomized and observational studies indicate that antimicrobial therapy, usually with a macrolide and another agent, has moderate success in clearing the lymphadenitis without surgical excision (resolution rates range from 50 to 100 percent) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/39,57,59,63-67\" class=\"abstract_t\">39,57,59,63-67</a>]. However, patients who are treated with antibiotics alone may develop fistulous sinus tracts [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/57\" class=\"abstract_t\">57</a>].</p><p>In a randomized trial comparing surgical excision with antimycobacterial therapy with <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> and <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a> for at least 12 weeks (and up to six months), 66 percent of patients treated with antibiotics were cured (defined as regression of the lymph node enlargement by at least 75 percent, cure of the fistula, and total skin closure without local recurrence or de novo lesions after six months), 32 percent developed draining fistula, and 78 percent had adverse effects related to medication or disease (eg, fever, fatigue, abdominal pain, tooth discoloration, headache, vomiting) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/57\" class=\"abstract_t\">57</a>]. It is important to warn families about the possibility of developing a draining fistula before starting antimycobacterial therapy.</p><p class=\"headingAnchor\" id=\"H2272513110\"><span class=\"h3\">Regimen</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The majority of NTM lymphadenitis is caused by MAC [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In the United States, <em>M. simiae </em>and<em> M. fortuitum</em> are less common causes [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/11\" class=\"abstract_t\">11</a>]. <em>M. haemophilum</em> is more commonly isolated in the Netherlands and other countries [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/12-15\" class=\"abstract_t\">12-15</a>].</p><p>Given the predominance of MAC in pediatric cervicofacial lymphadenitis, when antimicrobial treatment for NTM lymphadenitis is undertaken, and <em>M. tuberculosis</em> is not a concern, we suggest empiric therapy with a macrolide (<a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> or <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a>) in combination with <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a> <span class=\"nowrap\">and/or</span> <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a> (or <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a>) (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>].</p><p>This regimen is suggested based upon those in randomized trials, observational studies, and in vitro studies, with the caveat that, with the exception of macrolides and MAC, there is poor correlation between in vitro susceptibilities and clinical outcomes [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/24,39,57,64,66,67\" class=\"abstract_t\">24,39,57,64,66,67</a>]. Our suggested regimen is consistent with the recommendations of the American Thoracic Society, IDSA, and the AAP Committee on Infectious Diseases [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,9\" class=\"abstract_t\">2,9</a>].</p><p><a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">Clarithromycin</a> was used in early studies of MAC lymphadenitis; however, <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> may be preferable because it is more palatable and is dosed once per day [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/68,69\" class=\"abstract_t\">68,69</a>]. Although MAC is usually susceptible to macrolides, single-drug therapy with a macrolide increases the risk of development of mutational resistance [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>].</p><p>When antimicrobial therapy is undertaken in young (preschool-aged) children with suspected NTM lymphadenitis in whom <em>M. tuberculosis</em> remains a concern (eg, pending culture results in children with risk factors for <em>M. tuberculosis</em>, tuberculin skin testing [TST] with &ge;15 mm of induration), the empiric antimicrobial regimen should include coverage for both NTM and <em>M. tuberculosis</em>. One such regimen includes four drugs: <a href=\"topic.htm?path=isoniazid-pediatric-drug-information\" class=\"drug drug_pediatric\">isoniazid</a>, <a href=\"topic.htm?path=rifampin-rifampicin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifampin</a>, <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>, and a macrolide (either <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a> or <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>) (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 2</a>). For older children, in whom NTM lymphadenitis is far less common than in younger children, if there is a concern for NTM as an etiology, a macrolide can be added to standard four-drug <em>M. tuberculosis</em> therapy (isoniazid, rifampin, ethambutol, and <a href=\"topic.htm?path=pyrazinamide-pediatric-drug-information\" class=\"drug drug_pediatric\">pyrazinamide</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/70\" class=\"abstract_t\">70</a>]. Young children may not tolerate the volume of medication required for a five-drug regimen. The antibiotic regimen may need to be altered when definitive speciation is available. (See <a href=\"topic.htm?path=tuberculosis-disease-in-children#H20\" class=\"medical medical_review\">&quot;Tuberculosis disease in children&quot;, section on 'Treatment'</a>.)</p><p>The antibiotic regimen may need to be altered if a species other than MAC is isolated.</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>M. simiae</em></strong> &ndash; The optimal therapeutic regimen for <em>M. simiae</em> has yet to be determined [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Agents that appear to be active in vitro include <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>, <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a>, <a href=\"topic.htm?path=clofazimine-united-states-available-via-national-hansens-disease-program-and-fda-investigational-drug-ind-protocol-only-pediatric-drug-information\" class=\"drug drug_pediatric\">clofazimine</a> (not available in the United States), <a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">streptomycin</a>, and <a href=\"topic.htm?path=moxifloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">moxifloxacin</a> [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/71\" class=\"abstract_t\">71</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>M. fortuitum</em></strong> &ndash; <em>M. fortuitum</em> typically is susceptible to macrolides, <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a>, carbapenems, fluoroquinolones, and <a href=\"topic.htm?path=trimethoprim-sulfamethoxazole-co-trimoxazole-pediatric-drug-information\" class=\"drug drug_pediatric\">trimethoprim-sulfamethoxazole</a> (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 2</a>) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2,72-77\" class=\"abstract_t\">2,72-77</a>]. Single-agent therapy with a macrolide is not recommended because <em>M. fortuitum</em> has inducible macrolide resistance [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/78\" class=\"abstract_t\">78</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong><em>M. haemophilum</em></strong> &ndash; The optimal therapeutic regimen for <em>M. haemophilum</em> has yet to be determined [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>]. Agents that appear to be active in vitro include <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a>, <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a>, <a href=\"topic.htm?path=ciprofloxacin-pediatric-drug-information\" class=\"drug drug_pediatric\">ciprofloxacin</a>, and rifamycins [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/79-83\" class=\"abstract_t\">79-83</a>].</p><p/><p class=\"headingAnchor\" id=\"H2473624811\"><span class=\"h3\">Adverse effects</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The antimycobacterial agents that are used to treat NTM lymphadenitis often are difficult to tolerate, and some have important toxicities. Important adverse effects include (but are not limited to) ototoxicity and nephrotoxicity with <a href=\"topic.htm?path=amikacin-pediatric-drug-information\" class=\"drug drug_pediatric\">amikacin</a> and <a href=\"topic.htm?path=streptomycin-pediatric-drug-information\" class=\"drug drug_pediatric\">streptomycin</a>, optic neuropathy with <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>, and hepatotoxicity with <a href=\"topic.htm?path=isoniazid-pediatric-drug-information\" class=\"drug drug_pediatric\">isoniazid</a>. The adverse effects of the agents used to treat NTM infections are discussed in greater detail separately. (See <a href=\"topic.htm?path=pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity\" class=\"medical medical_review\">&quot;Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity&quot;</a> and <a href=\"topic.htm?path=manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity\" class=\"medical medical_review\">&quot;Manifestations of and risk factors for aminoglycoside nephrotoxicity&quot;</a> and <a href=\"topic.htm?path=ethambutol-an-overview\" class=\"medical medical_review\">&quot;Ethambutol: An overview&quot;</a> and <a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin\" class=\"medical medical_review\">&quot;Azithromycin, clarithromycin, and telithromycin&quot;</a> and <a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">&quot;Rifamycins (rifampin, rifabutin, rifapentine)&quot;</a> and <a href=\"topic.htm?path=isoniazid-an-overview\" class=\"medical medical_review\">&quot;Isoniazid: An overview&quot;</a> and <a href=\"topic.htm?path=isoniazid-hepatotoxicity\" class=\"medical medical_review\">&quot;Isoniazid hepatotoxicity&quot;</a> and <a href=\"topic.htm?path=aminoglycosides#H27\" class=\"medical medical_review\">&quot;Aminoglycosides&quot;, section on 'Toxicity'</a>.)</p><p class=\"headingAnchor\" id=\"H2272513118\"><span class=\"h3\">Duration</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The optimal duration of antimycobacterial therapy for lymphadenitis is unknown; patients typically are treated until their symptoms resolve (usually three to six months) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/17,57\" class=\"abstract_t\">17,57</a>].</p><p class=\"headingAnchor\" id=\"H2272513126\"><span class=\"h3\">Response to therapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The response to antimicrobial therapy for NTM lymphadenitis is monitored clinically. We suggest follow-up visits at approximately monthly intervals to ensure that patients are taking and tolerating their medications (if prescribed) and that their lymphadenitis is improving.</p><p class=\"headingAnchor\" id=\"H2272513134\"><span class=\"h3\">Treatment failure</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no standard definition for treatment failure. We consider patients who have no improvement of symptoms after six months of therapy or who have progression of symptoms during therapy to have treatment failure.</p><p>For children who are not responding to what should be effective therapy, it is important to verify speciation and susceptibility testing and to make sure that the child has received antimycobacterial therapy as prescribed, recognizing that with the exception of macrolides and MAC, there is poor correlation between in vitro susceptibilities and clinical outcomes.</p><p>Surgical excision, if it can be safely performed, may be warranted for patients who fail to improve or worsen during antimicrobial therapy for NTM lymphadenitis. (See <a href=\"#H2272513063\" class=\"local\">'Surgical excision'</a> above.)</p><p>For patients who are not surgical candidates, a change in the antimicrobial regimen <span class=\"nowrap\">and/or</span> testing for <a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> resistance may be warranted [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H2272513142\"><span class=\"h2\">Observation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>We do not usually suggest observation for children with NTM lymphadenitis, but it may be a feasible approach for families wishing to avoid surgery. Given enough time, children with isolated NTM lymphadenitis will have resolution of disease without treatment [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/13,54,63\" class=\"abstract_t\">13,54,63</a>]. However, many children with untreated NTM lymphadenitis develop sinus tracts with prolonged drainage [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10,63\" class=\"abstract_t\">10,63</a>]. Most <span class=\"nowrap\">parents/patients</span> are not willing to tolerate an unsightly, potentially draining lesion on the face or neck for the six months (or longer) that may be required for spontaneous healing [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/58\" class=\"abstract_t\">58</a>]. However, in a cohort of 21 children with confirmed craniofacial NTM cervical lymphadenitis managed by observation alone whose parents completed a satisfaction questionnaire at a median of 6.8 years after presentation, all but one respondent expressed contentment with observation alone as a management strategy [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/84\" class=\"abstract_t\">84</a>].</p><p>Antibiotic therapy (<a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> and <a href=\"topic.htm?path=rifabutin-pediatric-drug-information\" class=\"drug drug_pediatric\">rifabutin</a> for 12 weeks) and observation were compared in a small randomized trial in 50 immunocompetent children with advanced NTM lymphadenitis (defined by fluctuance and skin discoloration and microbiologically confirmed by culture or PCR of fine needle aspirates) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/63\" class=\"abstract_t\">63</a>]. The median time to resolution (regression of the lymph node enlargement by &ge;75 percent, cured fistula and total skin closure, and lack of recurrence or de novo lesions) was similar between groups (36 versus 40 weeks in the treatment and observation groups, respectively). In follow-up of at least two years, no recurrences were reported. Although these findings suggest that antimicrobial therapy may provide no benefit over observation, the study may have been underpowered to detect a difference. Another limitation is the relatively short duration of antimicrobial therapy.</p><p>In an observational study in 92 children who had NTM cervical lymphadenitis and minimal disease (the majority had involvement of only one node, and only one quarter had overlying skin changes), purulent drainage lasted three to five weeks in 84 children (91 percent) and eight weeks in five children (5 percent) [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/13\" class=\"abstract_t\">13</a>]. Seventy-one percent of the children had complete resolution of the symptoms in three to six months, 25 percent within nine months, and 2 percent within 12 months. In the observational study of 21 children with confirmed craniofacial NTM lymphadenitis described above [<a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/84\" class=\"abstract_t\">84</a>], at a median of 6.8 years follow-up (range 2.3 to 16.9 years), 18 patients had &ge;1 scar. Most of the scars were &le;3 cm in length with normal pigmentation and a normal or only mildly uneven surface.</p><p class=\"headingAnchor\" id=\"H2272513150\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphadenitis is the most common manifestation of nontuberculous mycobacterial (NTM) disease in otherwise healthy children. (See <a href=\"#H2272512883\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The majority of cases of NTM lymphadenitis are caused by <em>Mycobacterium avium</em> complex (MAC). Other commonly isolated species include <em>M. haemophilum, M. simiae</em>, and<em> M. fortuitum</em>. (See <a href=\"#H2272512896\" class=\"local\">'Microbiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NTM lymphadenitis typically occurs in immune-competent children between one and five years of age and involves the cervicofacial lymph nodes. It typically begins as a unilateral, nontender node that slowly enlarges over several weeks, during which fluctuance, violaceous discoloration, thinning of the overlying skin, and sinus drainage may develop (<a href=\"image.htm?imageKey=PEDS%2F69475\" class=\"graphic graphic_picture graphicRef69475 \">picture 1</a>). (See <a href=\"#H2272512912\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Children with NTM lymphadenitis usually have normal complete blood count, differential, erythrocyte sedimentation rate, and chest radiograph. (See <a href=\"#H2272512928\" class=\"local\">'Laboratory features'</a> above and <a href=\"#H2272512920\" class=\"local\">'Radiographic features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Definitive diagnosis requires isolation of NTM from culture or polymerase chain reaction of fistula drainage, tissue, or caseous material. In the absence of isolation of NTM, a presumptive diagnosis can be made if the clinical (eg, <span class=\"nowrap\">subacute/chronic</span> unilateral lymphadenitis, violaceous discoloration) <span class=\"nowrap\">and/or</span> histopathologic features (eg, positive acid-fast bacilli stains, granulomas) are compatible with NTM and other conditions in the differential diagnosis (including <em>M. tuberculosis</em>) have been excluded. (See <a href=\"#H2272512951\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis of NTM lymphadenitis includes other infectious causes of unilateral lymphadenitis, benign cysts, and malignancy. A combination of clinical, radiographic, and laboratory findings (including serology and microbiologic testing) may be necessary to distinguish NTM lymphadenitis from these conditions. (See <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-etiology-and-clinical-manifestations\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Etiology and clinical manifestations&quot;</a> and <a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">&quot;Cervical lymphadenitis in children: Diagnostic approach and initial management&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The management of NTM lymphadenitis in children may require surgery <span class=\"nowrap\">and/or</span> antimycobacterial therapy, in combination or sequentially (see <a href=\"#H2272513047\" class=\"local\">'Management'</a> above).</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with isolated NTM or suspected NTM lymphadenitis, we suggest surgical excision without antimicrobial therapy as the initial intervention if excision can be performed safely (eg, without damage to the facial nerve) (<a href=\"grade.htm?i=4\" class=\"grade\">Grade 2A</a>). (See <a href=\"#H2272513063\" class=\"local\">'Surgical excision'</a> above.)</p><p/><p class=\"bulletIndent2\"><span class=\"glyph\">&#8226;</span>For patients with NTM who are not candidates for surgical excision, we suggest antimicrobial therapy with or without gentle curettage (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). (See <a href=\"#H2272513102\" class=\"local\">'Antimycobacterial therapy'</a> above.)</p><p/><p class=\"bulletIndent2\">Given the predominance of MAC, pending culture results, we usually treat with a macrolide (<a href=\"topic.htm?path=clarithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">clarithromycin</a> or <a href=\"topic.htm?path=azithromycin-pediatric-drug-information\" class=\"drug drug_pediatric\">azithromycin</a>) in combination with another agent (either a rifamycin or <a href=\"topic.htm?path=ethambutol-pediatric-drug-information\" class=\"drug drug_pediatric\">ethambutol</a>) (<a href=\"image.htm?imageKey=PEDS%2F86161\" class=\"graphic graphic_table graphicRef86161 \">table 2</a>). The optimal duration of therapy is unknown; patients typically are treated until their symptoms resolve (usually three to six months). (See <a href=\"#H2272513102\" class=\"local\">'Antimycobacterial therapy'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/1\" class=\"nounderline abstract_t\">Fraser L, Moore P, Kubba H. Atypical mycobacterial infection of the head and neck in children: a 5-year retrospective review. Otolaryngol Head Neck Surg 2008; 138:311.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/2\" class=\"nounderline abstract_t\">Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/3\" class=\"nounderline abstract_t\">Bolan G, Reingold AL, Carson LA, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985; 152:1013.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/4\" class=\"nounderline abstract_t\">Celdr&aacute;n A, Esteban J, Ma&ntilde;as J, Granizo JJ. Wound infections due to Mycobacterium fortuitum after polypropylene mesh inguinal hernia repair. J Hosp Infect 2007; 66:374.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/5\" class=\"nounderline abstract_t\">Ferguson DD, Gershman K, Jensen B, et al. Mycobacterium goodii infections associated with surgical implants at Colorado hospital. Emerg Infect Dis 2004; 10:1868.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/6\" class=\"nounderline abstract_t\">McNabb A, Eisler D, Adie K, et al. Assessment of partial sequencing of the 65-kilodalton heat shock protein gene (hsp65) for routine identification of Mycobacterium species isolated from clinical sources. J Clin Microbiol 2004; 42:3000.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/7\" class=\"nounderline abstract_t\">Tortoli E. Impact of genotypic studies on mycobacterial taxonomy: the new mycobacteria of the 1990s. Clin Microbiol Rev 2003; 16:319.</a></li><li class=\"breakAll\">Mycobacterium. List of prokaryotic names with standing in nomenclature. www.bacterio.cict.fr/m/mycobacterium.html (Accessed on July 21, 2012).</li><li class=\"breakAll\">American Academy of Pediatrics. Diseases caused by nontuberculous mycobacteria. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.831.</li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/10\" class=\"nounderline abstract_t\">Wolinsky E. Mycobacterial lymphadenitis in children: a prospective study of 105 nontuberculous cases with long-term follow-up. Clin Infect Dis 1995; 20:954.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/11\" class=\"nounderline abstract_t\">Cruz AT, Ong LT, Starke JR. Mycobacterial infections in Texas children: a 5-year case series. Pediatr Infect Dis J 2010; 29:772.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/12\" class=\"nounderline abstract_t\">Lindeboom JA, Kuijper EJ, Prins JM, et al. Tuberculin skin testing is useful in the screening for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2006; 43:1547.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/13\" class=\"nounderline abstract_t\">Zeharia A, Eidlitz-Markus T, Haimi-Cohen Y, et al. Management of nontuberculous mycobacteria-induced cervical lymphadenitis with observation alone. Pediatr Infect Dis J 2008; 27:920.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/14\" class=\"nounderline abstract_t\">Cohen YH, Amir J, Ashkenazi S, et al. Mycobacterium haemophilum and lymphadenitis in immunocompetent children, Israel. Emerg Infect Dis 2008; 14:1437.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/15\" class=\"nounderline abstract_t\">Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008; 14:378.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/16\" class=\"nounderline abstract_t\">Garcia-Marcos PW, Plaza-Fornieles M, Menasalvas-Ruiz A, et al. Risk factors of non-tuberculous mycobacterial lymphadenitis in children: a case-control study. Eur J Pediatr 2017; 176:607.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/17\" class=\"nounderline abstract_t\">Chesney PJ. Nontuberculous mycobacteria. Pediatr Rev 2002; 23:300.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/18\" class=\"nounderline abstract_t\">Grange JM, Yates MD, Pozniak A. Bacteriologically confirmed non-tuberculous mycobacterial lymphadenitis in south east England: a recent increase in the number of cases. Arch Dis Child 1995; 72:516.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/19\" class=\"nounderline abstract_t\">Pham-Huy A, Robinson JL, Tapi&eacute;ro B, et al. Current trends in nontuberculous mycobacteria infections in Canadian children: A pediatric investigators collaborative network on infections in Canada (PICNIC) study. Paediatr Child Health 2010; 15:276.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/20\" class=\"nounderline abstract_t\">Vu TT, Daniel SJ, Quach C. Nontuberculous mycobacteria in children: a changing pattern. J Otolaryngol 2005; 34 Suppl 1:S40.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/21\" class=\"nounderline abstract_t\">Blyth CC, Best EJ, Jones CA, et al. Nontuberculous mycobacterial infection in children: a prospective national study. Pediatr Infect Dis J 2009; 28:801.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/22\" class=\"nounderline abstract_t\">Reuss AM, Wiese-Posselt M, Weissmann B, et al. Incidence rate of nontuberculous mycobacterial disease in immunocompetent children: a prospective nationwide surveillance study in Germany. Pediatr Infect Dis J 2009; 28:642.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/23\" class=\"nounderline abstract_t\">Haverkamp MH, Arend SM, Lindeboom JA, et al. Nontuberculous mycobacterial infection in children: a 2-year prospective surveillance study in the Netherlands. Clin Infect Dis 2004; 39:450.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/24\" class=\"nounderline abstract_t\">Tebruegge M, Pantazidou A, MacGregor D, et al. Nontuberculous Mycobacterial Disease in Children - Epidemiology, Diagnosis &amp; Management at a Tertiary Center. PLoS One 2016; 11:e0147513.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/25\" class=\"nounderline abstract_t\">Mangione EJ, Huitt G, Lenaway D, et al. Nontuberculous mycobacterial disease following hot tub exposure. Emerg Infect Dis 2001; 7:1039.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/26\" class=\"nounderline abstract_t\">Stout JE, Gadkowski LB, Rath S, et al. Pedicure-associated rapidly growing mycobacterial infection: an endemic disease. Clin Infect Dis 2011; 53:787.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/27\" class=\"nounderline abstract_t\">Lee WJ, Kim TW, Shur KB, et al. Sporotrichoid dermatosis caused by Mycobacterium abscessus from a public bath. J Dermatol 2000; 27:264.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/28\" class=\"nounderline abstract_t\">von Baum H, Bommer M, Forke A, et al. Is domestic tap water a risk for infections in neutropenic patients? Infection 2010; 38:181.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/29\" class=\"nounderline abstract_t\">Fleming GA, Frangoul H, Dermody TS, Halasa N. A cord blood transplant recipient with Mycobacterium mucogenicum central venous catheter infection after infusion of tap water. Pediatr Infect Dis J 2006; 25:567.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/30\" class=\"nounderline abstract_t\">Hall-Stoodley L, Stoodley P. Biofilm formation and dispersal and the transmission of human pathogens. Trends Microbiol 2005; 13:7.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/31\" class=\"nounderline abstract_t\">Haverkamp MH, Lindeboom JA, de Visser AW, et al. Nontuberculous mycobacterial cervicofacial lymphadenitis in children from the multicenter, randomized, controlled trial in The Netherlands: relevance of polymorphisms in candidate host immunity genes. Int J Pediatr Otorhinolaryngol 2010; 74:752.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/32\" class=\"nounderline abstract_t\">Romanus V, Hallander HO, W&aring;hl&eacute;n P, et al. Atypical mycobacteria in extrapulmonary disease among children. Incidence in Sweden from 1969 to 1990, related to changing BCG-vaccination coverage. Tuber Lung Dis 1995; 76:300.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/33\" class=\"nounderline abstract_t\">Katila ML, Brander E, Backman A. Neonatal BCG vaccination and mycobacterial cervical adenitis in childhood. Tubercle 1987; 68:291.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/34\" class=\"nounderline abstract_t\">Holland AJ, Holland J, Martin HC, et al. Noncervicofacial atypical mycobacterial lymphadenitis in childhood. J Pediatr Surg 2001; 36:1337.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/35\" class=\"nounderline abstract_t\">Lindeboom JA, Smets AM, Kuijper EJ, et al. The sonographic characteristics of nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Radiol 2006; 36:1063.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/36\" class=\"nounderline abstract_t\">Penn R, Steehler MK, Sokohl A, Harley EH. Nontuberculous mycobacterial cervicofacial lymphadenitis--a review and proposed classification system. Int J Pediatr Otorhinolaryngol 2011; 75:1599.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/37\" class=\"nounderline abstract_t\">Suskind DL, Handler SD, Tom LW, et al. Nontuberculous mycobacterial cervical adenitis. Clin Pediatr (Phila) 1997; 36:403.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/38\" class=\"nounderline abstract_t\">Staufner C, Sommerburg O, Holland-Cunz S. Algorithm for early diagnosis in nontuberculous mycobacterial lymphadenitis. Acta Paediatr 2012; 101:e382.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/39\" class=\"nounderline abstract_t\">Hazra R, Robson CD, Perez-Atayde AR, Husson RN. Lymphadenitis due to nontuberculous mycobacteria in children: presentation and response to therapy. Clin Infect Dis 1999; 28:123.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/40\" class=\"nounderline abstract_t\">Robson CD, Hazra R, Barnes PD, et al. Nontuberculous mycobacterial infection of the head and neck in immunocompetent children: CT and MR findings. AJNR Am J Neuroradiol 1999; 20:1829.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/41\" class=\"nounderline abstract_t\">Carvalho AC, Codecasa L, Pinsi G, et al. Differential diagnosis of cervical mycobacterial lymphadenitis in children. Pediatr Infect Dis J 2010; 29:629.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/42\" class=\"nounderline abstract_t\">Kraus M, Benharroch D, Kaplan D, et al. Mycobacterial cervical lymphadenitis: the histological features of non-tuberculous mycobacterial infection. Histopathology 1999; 35:534.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/43\" class=\"nounderline abstract_t\">Tunkel DE, Romaneschi KB. Surgical treatment of cervicofacial nontuberculous mycobacterial adenitis in children. Laryngoscope 1995; 105:1024.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/44\" class=\"nounderline abstract_t\">Haimi-Cohen Y, Zeharia A, Mimouni M, et al. Skin indurations in response to tuberculin testing in patients with nontuberculous mycobacterial lymphadenitis. Clin Infect Dis 2001; 33:1786.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/45\" class=\"nounderline abstract_t\">Detjen AK, Keil T, Roll S, et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin Infect Dis 2007; 45:322.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/46\" class=\"nounderline abstract_t\">Iversen RH, Illum P. Cervicofacial nontuberculous mycobacterial lymphadenitis in children. Dan Med J 2012; 59:A4349.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/47\" class=\"nounderline abstract_t\">Spyridis P, Maltezou HC, Hantzakos A, et al. Mycobacterial cervical lymphadenitis in children: clinical and laboratory factors of importance for differential diagnosis. Scand J Infect Dis 2001; 33:362.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/48\" class=\"nounderline abstract_t\">Scott CA, Atkinson SH, Sodha A, et al. Management of lymphadenitis due to non-tuberculous mycobacterial infection in children. Pediatr Surg Int 2012; 28:461.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/49\" class=\"nounderline abstract_t\">Taha AM, Davidson PT, Bailey WC. Surgical treatment of atypical mycobacterial lymphadenitis in children. Pediatr Infect Dis 1985; 4:664.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/50\" class=\"nounderline abstract_t\">Bruijnesteijn Van Coppenraet ES, Lindeboom JA, Prins JM, et al. Real-time PCR assay using fine-needle aspirates and tissue biopsy specimens for rapid diagnosis of mycobacterial lymphadenitis in children. J Clin Microbiol 2004; 42:2644.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/51\" class=\"nounderline abstract_t\">Lindeboom JA, Bruijnesteijn van Coppenraet LE, van Soolingen D, et al. Clinical manifestations, diagnosis, and treatment of Mycobacterium haemophilum infections. Clin Microbiol Rev 2011; 24:701.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/52\" class=\"nounderline abstract_t\">Richardson ET, Samson D, Banaei N. Rapid Identification of Mycobacterium tuberculosis and nontuberculous mycobacteria by multiplex, real-time PCR. J Clin Microbiol 2009; 47:1497.</a></li><li class=\"breakAll\">www.gen-probe.com/products-services/culture-identification (Accessed on July 10, 2012).</li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/54\" class=\"nounderline abstract_t\">Mandell DL, Wald ER, Michaels MG, Dohar JE. Management of nontuberculous mycobacterial cervical lymphadenitis. Arch Otolaryngol Head Neck Surg 2003; 129:341.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/55\" class=\"nounderline abstract_t\">Haustein T, Ridout DA, Hartley JC, et al. The likelihood of an indeterminate test result from a whole-blood interferon-gamma release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009; 28:669.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/56\" class=\"nounderline abstract_t\">Panesar J, Higgins K, Daya H, et al. Nontuberculous mycobacterial cervical adenitis: a ten-year retrospective review. Laryngoscope 2003; 113:149.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/57\" class=\"nounderline abstract_t\">Lindeboom JA, Kuijper EJ, Bruijnesteijn van Coppenraet ES, et al. Surgical excision versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children: a multicenter, randomized, controlled trial. Clin Infect Dis 2007; 44:1057.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/58\" class=\"nounderline abstract_t\">Starke JR. Commentary: The natural history of nontuberculous mycobacterial cervical adenitis. Pediatr Infect Dis J 2008; 27:923.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/59\" class=\"nounderline abstract_t\">Lindeboom JA. Surgical treatment for nontuberculous mycobacterial (NTM) cervicofacial lymphadenitis in children. J Oral Maxillofac Surg 2012; 70:345.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/60\" class=\"nounderline abstract_t\">Lindeboom JA, Lindeboom R, Bruijnesteijn van Coppenraet ES, et al. Esthetic outcome of surgical excision versus antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Pediatr Infect Dis J 2009; 28:1028.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/61\" class=\"nounderline abstract_t\">Parker NP, Scott AR, Finkelstein M, et al. Predicting surgical outcomes in pediatric cervicofacial nontuberculous mycobacterial lymphadenitis. Ann Otol Rhinol Laryngol 2012; 121:478.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/62\" class=\"nounderline abstract_t\">Gonzalez CD, Petersen MG, Miller M, et al. Complex nontuberculous mycobacterial cervicofacial lymphadenitis: What is the optimal approach? Laryngoscope 2016; 126:1677.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/63\" class=\"nounderline abstract_t\">Lindeboom JA. Conservative wait-and-see therapy versus antibiotic treatment for nontuberculous mycobacterial cervicofacial lymphadenitis in children. Clin Infect Dis 2011; 52:180.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/64\" class=\"nounderline abstract_t\">Berger C, Pfyffer GE, Nadal D. Treatment of nontuberculous mycobacterial lymphadenitis with clarithromycin plus rifabutin. J Pediatr 1996; 128:383.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/65\" class=\"nounderline abstract_t\">Coulter JB, Lloyd DA, Jones M, et al. Nontuberculous mycobacterial adenitis: effectiveness of chemotherapy following incomplete excision. Acta Paediatr 2006; 95:182.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/66\" class=\"nounderline abstract_t\">Luong A, McClay JE, Jafri HS, Brown O. Antibiotic therapy for nontuberculous mycobacterial cervicofacial lymphadenitis. Laryngoscope 2005; 115:1746.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/67\" class=\"nounderline abstract_t\">Timmerman MK, Morley AD, Buwalda J. Treatment of non-tuberculous mycobacterial cervicofacial lymphadenitis in children: critical appraisal of the literature. Clin Otolaryngol 2008; 33:546.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/68\" class=\"nounderline abstract_t\">Steele RW, Thomas MP, B&eacute;gu&eacute; RE. Compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J 2001; 20:1.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/69\" class=\"nounderline abstract_t\">Matsui D, Lim R, Tschen T, Rieder MJ. Assessment of the palatability of beta-lactamase-resistant antibiotics in children. Arch Pediatr Adolesc Med 1997; 151:599.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/70\" class=\"nounderline abstract_t\">Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016; 63:e147.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/71\" class=\"nounderline abstract_t\">van Ingen J, Totten SE, Heifets LB, et al. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease. Int J Antimicrob Agents 2012; 39:173.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/72\" class=\"nounderline abstract_t\">Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae. Antimicrob Agents Chemother 1985; 28:807.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/73\" class=\"nounderline abstract_t\">Brown BA, Wallace RJ Jr, Onyi GO, et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992; 36:180.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/74\" class=\"nounderline abstract_t\">Wallace RJ Jr, Brown BA, Onyi GO. Susceptibilities of Mycobacterium fortuitum biovar. fortuitum and the two subgroups of Mycobacterium chelonae to imipenem, cefmetazole, cefoxitin, and amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991; 35:773.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/75\" class=\"nounderline abstract_t\">Wallace RJ Jr, Brown BA, Onyi GO. Skin, soft tissue, and bone infections due to Mycobacterium chelonae chelonae: importance of prior corticosteroid therapy, frequency of disseminated infections, and resistance to oral antimicrobials other than clarithromycin. J Infect Dis 1992; 166:405.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/76\" class=\"nounderline abstract_t\">Wallace RJ Jr, Brown-Elliott BA, Ward SC, et al. Activities of linezolid against rapidly growing mycobacteria. Antimicrob Agents Chemother 2001; 45:764.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/77\" class=\"nounderline abstract_t\">Wallace RJ Jr, Bedsole G, Sumter G, et al. Activities of ciprofloxacin and ofloxacin against rapidly growing mycobacteria with demonstration of acquired resistance following single-drug therapy. Antimicrob Agents Chemother 1990; 34:65.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/78\" class=\"nounderline abstract_t\">Nash KA, Brown-Elliott BA, Wallace RJ Jr. A novel gene, erm(41), confers inducible macrolide resistance to clinical isolates of Mycobacterium abscessus but is absent from Mycobacterium chelonae. Antimicrob Agents Chemother 2009; 53:1367.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/79\" class=\"nounderline abstract_t\">Kiehn TE, White M. Mycobacterium haemophilum: an emerging pathogen. Eur J Clin Microbiol Infect Dis 1994; 13:925.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/80\" class=\"nounderline abstract_t\">Atkinson BA, Bocanegra R, Graybill JR. Treatment of Mycobacterium haemophilum infection in a murine model with clarithromycin, rifabutin, and ciprofloxacin. Antimicrob Agents Chemother 1995; 39:2316.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/81\" class=\"nounderline abstract_t\">McBride ME, Rudolph AH, Tschen JA, et al. Diagnostic and therapeutic considerations for cutaneous Mycobacterium haemophilum infections. Arch Dermatol 1991; 127:276.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/82\" class=\"nounderline abstract_t\">Kristjansson M, Bieluch VM, Byeff PD. Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature. Rev Infect Dis 1991; 13:906.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/83\" class=\"nounderline abstract_t\">Plemmons RM, McAllister CK, Garces MC, Ward RL. Osteomyelitis due to Mycobacterium haemophilum in a cardiac transplant patient: case report and analysis of interactions among clarithromycin, rifampin, and cyclosporine. Clin Infect Dis 1997; 24:995.</a></li><li><a href=\"https://www.uptodate.com/contents/nontuberculous-mycobacterial-lymphadenitis-in-children/abstract/84\" class=\"nounderline abstract_t\">Haimi-Cohen Y, Markus-Eidlitz T, Amir J, Zeharia A. Long-term Follow-up of Observation-Only Management of Nontuberculous Mycobacterial Lymphadenitis. Clin Pediatr (Phila) 2016; 55:1160.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 86045 Version 13.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H2272513150\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H2272512883\" id=\"outline-link-H2272512883\">INTRODUCTION</a></li><li><a href=\"#H2272512896\" id=\"outline-link-H2272512896\">MICROBIOLOGY</a></li><li><a href=\"#H2272512904\" id=\"outline-link-H2272512904\">EPIDEMIOLOGY</a></li><li><a href=\"#H2272512912\" id=\"outline-link-H2272512912\">CLINICAL FEATURES</a></li><li><a href=\"#H2272512920\" id=\"outline-link-H2272512920\">RADIOGRAPHIC FEATURES</a></li><li><a href=\"#H2272512928\" id=\"outline-link-H2272512928\">LABORATORY FEATURES</a><ul><li><a href=\"#H2272512935\" id=\"outline-link-H2272512935\">Acid-fast bacilli stains and histopathology</a></li><li><a href=\"#H2272512943\" id=\"outline-link-H2272512943\">Other tests</a></li></ul></li><li><a href=\"#H2272512951\" id=\"outline-link-H2272512951\">DIAGNOSIS</a><ul><li><a href=\"#H2377830849\" id=\"outline-link-H2377830849\">Overview</a></li><li><a href=\"#H2272512967\" id=\"outline-link-H2272512967\">Clinical suspicion</a></li><li><a href=\"#H2443737761\" id=\"outline-link-H2443737761\">Tuberculin skin testing</a></li><li><a href=\"#H2443738274\" id=\"outline-link-H2443738274\">Microbiology/histopathology</a></li></ul></li><li><a href=\"#H2272513023\" id=\"outline-link-H2272513023\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H2272513031\" id=\"outline-link-H2272513031\">M. tuberculosis</a></li><li><a href=\"#H2272513039\" id=\"outline-link-H2272513039\">Other conditions</a></li></ul></li><li><a href=\"#H2272513047\" id=\"outline-link-H2272513047\">MANAGEMENT</a><ul><li><a href=\"#H2272513063\" id=\"outline-link-H2272513063\">Surgical excision</a><ul><li><a href=\"#H2377831009\" id=\"outline-link-H2377831009\">- Indications</a></li><li><a href=\"#H2272513071\" id=\"outline-link-H2272513071\">- Postoperative follow-up</a></li><li><a href=\"#H2272513094\" id=\"outline-link-H2272513094\">- Postoperative recurrence</a></li></ul></li><li><a href=\"#H2272513102\" id=\"outline-link-H2272513102\">Antimycobacterial therapy</a><ul><li><a href=\"#H2377831016\" id=\"outline-link-H2377831016\">- Indications</a></li><li><a href=\"#H2272513110\" id=\"outline-link-H2272513110\">- Regimen</a></li><li><a href=\"#H2473624811\" id=\"outline-link-H2473624811\">- Adverse effects</a></li><li><a href=\"#H2272513118\" id=\"outline-link-H2272513118\">- Duration</a></li><li><a href=\"#H2272513126\" id=\"outline-link-H2272513126\">- Response to therapy</a></li><li><a href=\"#H2272513134\" id=\"outline-link-H2272513134\">- Treatment failure</a></li></ul></li><li><a href=\"#H2272513142\" id=\"outline-link-H2272513142\">Observation</a></li></ul></li><li><a href=\"#H2272513150\" id=\"outline-link-H2272513150\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PEDS/86045|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=NEURO/55677\" class=\"graphic graphic_figure\">- Facial nerve anatomy</a></li></ul></li><li><div id=\"PEDS/86045|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PEDS/69475\" class=\"graphic graphic_picture\">- Mycobacterium avium adenitis</a></li></ul></li><li><div id=\"PEDS/86045|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/61936\" class=\"graphic graphic_table\">- Mycobacteria classification</a></li><li><a href=\"image.htm?imageKey=PEDS/86161\" class=\"graphic graphic_table\">- Treatment NTM children</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aminoglycosides\" class=\"medical medical_review\">Aminoglycosides</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=azithromycin-clarithromycin-and-telithromycin\" class=\"medical medical_review\">Azithromycin, clarithromycin, and telithromycin</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cervical-lymphadenitis-in-children-diagnostic-approach-and-initial-management\" class=\"medical medical_review\">Cervical lymphadenitis in children: Diagnostic approach and initial management</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=cervical-lymphadenitis-in-children-etiology-and-clinical-manifestations\" class=\"medical medical_review\">Cervical lymphadenitis in children: Etiology and clinical manifestations</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=disseminated-nontuberculous-mycobacterial-ntm-infections-and-ntm-bacteremia-in-children\" class=\"medical medical_review\">Disseminated nontuberculous mycobacterial (NTM) infections and NTM bacteremia in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-of-nontuberculous-mycobacterial-infections\" class=\"medical medical_review\">Epidemiology of nontuberculous mycobacterial infections</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=ethambutol-an-overview\" class=\"medical medical_review\">Ethambutol: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isoniazid-hepatotoxicity\" class=\"medical medical_review\">Isoniazid hepatotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=isoniazid-an-overview\" class=\"medical medical_review\">Isoniazid: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=manifestations-of-and-risk-factors-for-aminoglycoside-nephrotoxicity\" class=\"medical medical_review\">Manifestations of and risk factors for aminoglycoside nephrotoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=microbiology-of-nontuberculous-mycobacteria\" class=\"medical medical_review\">Microbiology of nontuberculous mycobacteria</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nontuberculous-mycobacterial-pulmonary-infections-in-children\" class=\"medical medical_review\">Nontuberculous mycobacterial pulmonary infections in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=nontuberculous-mycobacterial-skin-and-soft-tissue-infections-in-children\" class=\"medical medical_review\">Nontuberculous mycobacterial skin and soft tissue infections in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-and-prevention-of-aminoglycoside-nephrotoxicity-and-ototoxicity\" class=\"medical medical_review\">Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=rifamycins-rifampin-rifabutin-rifapentine\" class=\"medical medical_review\">Rifamycins (rifampin, rifabutin, rifapentine)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculosis-disease-in-children\" class=\"medical medical_review\">Tuberculosis disease in children</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=tuberculous-lymphadenitis\" class=\"medical medical_review\">Tuberculous lymphadenitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=use-of-interferon-gamma-release-assays-for-diagnosis-of-latent-tuberculosis-infection-tuberculosis-screening-in-adults\" class=\"medical medical_review\">Use of interferon-gamma release assays for diagnosis of latent tuberculosis infection (tuberculosis screening) in adults</a></li></ul></div></div>","javascript":null}